Skip to main content
. Author manuscript; available in PMC: 2014 Oct 16.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2012 Nov 22;85(5):1206–1211. doi: 10.1016/j.ijrobp.2012.10.008

Figure 2. Overall survival.

Figure 2

The median OS for patients treated on RTOG 0211 per protocol or with acceptable deviation was 11.5 months versus 11.0 months for historical controls treated by RT alone (HR (0211 v. historical control) = 1.14; 95%CI: 0.94 – 1.37; p (one-sided) = 0.91).

HHS Vulnerability Disclosure